Our technologies
We are changing the paradigm of immunotherapies with our next-generation multi-specific antibodies
Autoregulation platform
NovalGen’s proprietary ground-breaking autoregulation technology platform enables the maximum efficacy to be unleashed from a therapy whilst ensuring a manageable safety profile by limiting life threatening toxicities.
Our antibodies
Read more about our ROR1 bispecifc antibody and its MoA
Key capabilities
Novalgen is a fully integrated company capable of developing breakthrough therapies.